Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study
- PMID: 35153138
- DOI: 10.1016/j.hbpd.2022.01.006
Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) was recently proposed to be renamed metabolic dysfunction-associated fatty liver disease (MAFLD) with the diagnostic criteria revised. We investigated the similarities and differences in the prevalence and clinical characteristics of MAFLD and NAFLD in Chinese adults.
Methods: A cross-sectional study of 9980 Chinese individuals aged 40 years or older was performed between 2011 and 2012 using randomized, stratified cluster sampling in Shanghai, China. A detailed questionnaire and the results of abdominal ultrasonography, a standardized 2-h 75-g oral glucose tolerance test and blood biochemical examinations were collected.
Results: A total of 9927 subjects were included in this study. The prevalence of MAFLD (40.3%) was significantly higher than that of NAFLD (36.9%) (P < 0.05). MAFLD was highly prevalent in type 2 diabetes mellitus (T2DM) (53.8%), impaired fasting glucose (35.7%) and impaired glucose tolerance (40.9%). High risk of advanced fibrosis based on fibrosis-4 was highly prevalent (14.7%) in lean MAFLD with T2DM. Among 9927 subjects, 3481 (35.1%) fulfilled the diagnostic criteria for MAFLD and NAFLD (MAFLD+NAFLD+), 521 (5.2%) MAFLD+NAFLD-, and 181 (1.8%) MAFLD-NAFLD+. The MAFLD+NAFLD- group had more significant metabolic disorders than those in the MAFLD+NAFLD+ group (all P < 0.05). Among MAFLD-NAFLD+ subjects, 82.9% had metabolic disorders.
Conclusions: The new definition of MAFLD may better reflect the pathogenesis related to metabolism. Future research should focus on studying the natural history, pathogenesis and treatment effectivity of the overlap and non-overlap of NAFLD and MAFLD subjects.
Keywords: Metabolic dysfunction-associated fatty liver disease; Nonalcoholic fatty liver disease; Oral glucose tolerance test; Prevalence.
Copyright © 2022. Published by Elsevier B.V.
Comment in
-
NAFLD or MAFLD: That is the conundrum.Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):103-105. doi: 10.1016/j.hbpd.2022.01.008. Epub 2022 Jan 31. Hepatobiliary Pancreat Dis Int. 2022. PMID: 35125337 No abstract available.
Similar articles
-
A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.BMC Gastroenterol. 2022 Nov 19;22(1):471. doi: 10.1186/s12876-022-02576-4. BMC Gastroenterol. 2022. PMID: 36402947 Free PMC article.
-
Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.Hepatology. 2022 Feb;75(2):419-429. doi: 10.1002/hep.32131. Epub 2021 Dec 13. Hepatology. 2022. PMID: 34453359 Free PMC article.
-
Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.J Clin Endocrinol Metab. 2022 Jan 18;107(2):e745-e755. doi: 10.1210/clinem/dgab644. J Clin Endocrinol Metab. 2022. PMID: 34467980
-
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2. Eur J Clin Invest. 2021. PMID: 33583033 Review.
-
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.Clin Mol Hepatol. 2022 Oct;28(4):790-801. doi: 10.3350/cmh.2022.0070. Epub 2022 May 11. Clin Mol Hepatol. 2022. PMID: 35545437 Free PMC article. Review.
Cited by
-
The global burden of fatty liver disease: the major impact of China.Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):119-123. doi: 10.21037/hbsn-23-556. Epub 2024 Jan 12. Hepatobiliary Surg Nutr. 2024. PMID: 38322226 Free PMC article. No abstract available.
-
Sex-Specific Contribution of Cardiometabolic Index in Predicting Metabolic Dysfunction-Associated Fatty Liver Disease: Insights from a General Population.Diabetes Metab Syndr Obes. 2023 Nov 30;16:3871-3883. doi: 10.2147/DMSO.S437413. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 38054037 Free PMC article.
-
Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study.Lipids Health Dis. 2023 Oct 28;22(1):185. doi: 10.1186/s12944-023-01947-4. Lipids Health Dis. 2023. PMID: 37898739 Free PMC article.
-
Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus.Diabetes Metab Syndr Obes. 2023 Aug 7;16:2345-2354. doi: 10.2147/DMSO.S418020. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37577041 Free PMC article.
-
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes.Hepatol Int. 2023 Oct;17(5):1082-1097. doi: 10.1007/s12072-023-10568-z. Epub 2023 Aug 9. Hepatol Int. 2023. PMID: 37556065 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
